BioSpace News Archive

NanoDx, Inc., a developer of breakthrough point-of-care diagnostic solutions and SkyWater Technology, the trusted technology realization partner, announced the first commercially ready nano biosensor to yield a protein response.

Genexine announced the dosing of the first patient in phase 2 clinical trial using triple combination therapy in patients with recurrent/metastatic HNSCC.

CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, today announced the company has secured $7.2 million in funding from existing investors.

AUM LifeTech, Inc., a Philadelphia-based preclinical stage biotechnology company, has received a Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to advance their preclinical program in lung cancer immunotherapy using a non-viral RNA-targeting gene therapy approach.

Molecular spectrometry examines and quantifies the response of molecules on interaction with known amounts of energy.

The revenue generation opportunities in the diabetic nephropathy market have been attributed to the increasing count of geriatric population that are encountering diabetic nephropathy.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new health equity collaboration with the Satcher Health Leadership Institute (SHLI) at Morehouse School of Medicine and the Center for Minority Health and Health Disparities Research and Education (CMHDRE) at Xavier University of Louisiana’s College of Pharmacy.

Wilmington, Delaware, United States, Transparency Market Research Inc. – The escalating prevalence of chronic disease, cancer, and the rising numbers of cardiovascular diseases among a considerable chunk of the populace will bring good growth prospects for the ablation devices market during the forecast period of 2018-2026

Wilmington, Delaware, United States, Transparency Market Research Inc. – Clinical alarms are used to warn caregivers of potential adverse or immediate patient conditions.

By End User, Hospitals Are Expected To Account For Bulk Of The Demand For Lithotripsy Devices To Address Gall Bladder & Kidney Stones